ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera

ENvue Medical (NASDAQ: FEED) received a USPTO Notice of Allowance for Application No. 18/199,059 titled "Feeding Tube with Electromagnetic Sensor and Camera" on Feb 24, 2026.

Rhea-AI Summary

ENvue Medical (NASDAQ: FEED) received a USPTO Notice of Allowance for Application No. 18/199,059 titled "Feeding Tube with Electromagnetic Sensor and Camera" on Feb 24, 2026. The allowed patent includes 18 claims combining distal-tip camera imaging, embedded electromagnetic sensing, and MRI safety design elements.

ENvue says the invention aims to enable real-time visualization plus continuous positional tracking to improve placement confidence and support future product development of the ENvue Navigation Platform.

Positive

• Notice of Allowance for patent application No. 18/199,059 covering combined EM navigation and camera
• 18 claims granted covering distal-tip camera, embedded EM sensor architecture, and combined navigation/visualization
• MRI safety design elements included to control RF-induced heating below defined thresholds

Negative

• None.

Argus Feb 24 session

+5.60% close to close Open Argus

Details

News Market Reaction – FEED

On Feb 24, the day this news came out, FEED closed 5.60% above the previous close.

Data tracked by StockTitan Argus for the Feb 24 session.

Market Context

On Feb 24, the day this news came out, the stock closed 5.6% above the previous close. A strong posi...

Analysis

On Feb 24, the day this news came out, the stock closed 5.6% above the previous close. A strong positive reaction aligns with ENvue’s strategy of building a differentiated enteral access platform backed by IP. The Notice of Allowance secures protection for a feeding tube that combines electromagnetic navigation with an internal camera, tied to a patent family with priority dating to 2017 and 18 allowed claims. Investors might also weigh the company’s history of both sharp gains and selloffs around prior product and partnership news when assessing durability.

Key Figures

Patent application number: 18/199,059 Allowed claims: 18 claims Priority date: 2017

Patent application number

18/199,059

USPTO Notice of Allowance for feeding tube patent

Allowed claims

18 claims

Feeding tube with electromagnetic sensor and camera

Priority date

2017

Broader patent family priority dating back to 2017

Historical Context

5 past events · Latest: Jan 28

5 events

1. Jan 28

   Distribution partnership

   24h Move

   +119.0%

   Nationwide U-Deliver deal for OTC reusable ENFit syringe distribution.

2. Jan 21

   Leadership appointment

   24h Move

   +2.4%

   Hiring veteran VP Commercial to expand U.S. commercialization footprint.

3. Jan 14

   Product launch

   24h Move

   -26.7%

   Launch of OTC reusable ENFit syringes for enteral feeding and medication.

4. Jan 09

   Clinical program

   24h Move

   -7.6%

   Program to apply NanoVibronix vibration tech to reduce NG-tube pain.

5. Jan 08

   Visibility event

   24h Move

   +11.1%

   Nasdaq opening-bell ceremony highlighting enteral and pain technologies.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

electromagnetic navigation, distal-tip camera, electromagnetic sensor, MRI, +2 more

6 terms

electromagnetic navigation technical

"combines electromagnetic navigation with an integrated distal-tip camera"

Electromagnetic navigation is a medical guidance system that creates a virtual map and uses weak magnetic fields to track tiny sensors on instruments as they move inside the body, similar to using GPS to find a route in a city. It matters to investors because this technology can make complex procedures less invasive, expand the market for diagnostic and surgical devices, and influence product sales, reimbursement and regulatory approval timelines that affect company value.

distal-tip camera technical

"a distal-tip camera integrated into the feeding tube for real-time internal visualization"

A distal-tip camera is a tiny video camera built into the far end of a medical tube or probe (such as an endoscope) that sends live images from inside the body to a display outside. Investors care because the camera’s size, image quality and reliability directly affect how well doctors can see and treat issues, which in turn influences a device’s clinical usefulness, regulatory approval, competitive edge and commercial success.

electromagnetic sensor technical

"“Feeding Tube with Electromagnetic Sensor and Camera,” Application No. 18/199,059"

An electromagnetic sensor is a device that detects or measures magnetic fields, electric fields, or the electromagnetic waves produced by objects and systems, converting those signals into readable data. For investors, these sensors matter because they are core components in products and operations across industries—from phones and cars to factory automation—so advances, supply constraints, or cost changes can affect a company’s product performance, manufacturing costs, and competitive position, like a compass giving actionable direction to a traveler.

MRI medical

"The application also includes MRI-related safety design elements"

Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives demand for imaging machines, hospital services, diagnostics and can be central to clinical trial results and regulatory decisions—changes in MRI use or technology can affect revenue, capital spending and reimbursement in healthcare and medical device markets.

RF-induced heating technical

"including controlled RF-induced heating below defined thresholds"

RF-induced heating is the temperature rise that happens when tissues or materials absorb radiofrequency energy from sources like medical scanners, implants, or wireless transmitters. It matters to investors because uncontrolled heating can harm patients, compromise implanted devices, trigger regulatory restrictions or recalls, and force costly product changes—similar to a phone overheating in sunlight, but occurring inside the body or a critical medical device.

enteral access medical

"a leader in advanced navigation technologies for enteral access"

Enteral access is a medical method for delivering food, fluids or medications directly into the stomach or intestines through a tube, either passed through the nose or placed through a small opening in the abdominal wall. For investors it signals demand for durable medical devices, supplies and procedures that provide ongoing revenue and influence hospital and home-care spending, reimbursement risks, and the size of patient populations served.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Technology supports the evolution of enteral access from blind procedures to real-time visualized placement

TYLER, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a leader in advanced navigation technologies for enteral access, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for the Company’s patent application titled “Feeding Tube with Electromagnetic Sensor and Camera,” Application No. 18/199,059.

The allowed patent includes 18 claims covering a feeding tube design that combines electromagnetic navigation with an integrated distal-tip camera, enabling both positional guidance and direct visualization during placement. The allowed claims include innovations such as a distal-tip camera integrated into the feeding tube for real-time internal visualization, an embedded electromagnetic sensor architecture for continuous positional tracking, and combined navigation and visualization capabilities intended to support placement confidence. The application also includes MRI-related safety design elements, including controlled RF-induced heating below defined thresholds. ENvue believes the addition of imaging capability may enhance clinical confidence during complex placements, reduce reliance on confirmatory procedures, and drive future product development in advanced visualization and smart navigation.

“We believe that this allowance reflects our long-term vision to evolve enteral access from blind or indirect methods to intelligent, visualized placement,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “Integrating electromagnetic guidance with direct internal visualization expands the clinical value of our platform and strengthens our ability to build a differentiated technology ecosystem. Upon issuance, we expect the patent to expand our intellectual property protection across both navigation and visualization, reinforcing the strength and breadth of our next-generation product development platform. We also expect it to further solidify our competitive positioning in the enteral access market and support the continued evolution of the ENvue™ Navigation Platform toward intelligent, visualized placement.”

The application is part of a broader patent family with priority dating back to 2017 and assigned to ENvue Medical Ltd., covering multiple generations of electromagnetic feeding tube technology.

About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:

• ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
• ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
• Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
  

Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com

Media Contact:
KCSA Strategic Communications
Raquel Cona, Vice President
PH: (516) 779-2630
envue@kcsa.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ENvue Medical (FEED) announce on February 24, 2026 about a new patent allowance?

ENvue Medical announced a USPTO Notice of Allowance for a feeding tube combining EM navigation and a camera. According to ENvue Medical, Application No. 18/199,059 includes 18 claims for integrated distal-tip imaging, embedded electromagnetic sensing, and MRI-related safety features.

How does the allowed patent for FEED’s feeding tube combine navigation and visualization?

The patent covers integration of a distal-tip camera with embedded electromagnetic sensors for concurrent tracking and imaging. According to ENvue Medical, the design enables continuous positional guidance alongside real-time internal visualization to support placement confidence in complex cases.

Will the FEED patent allowance affect ENvue Medical’s product development or competitive position?

ENvue expects the allowance to expand intellectual property protection and support next-generation development. According to ENvue Medical, the allowed claims aim to strengthen its navigation and visualization platform and solidify competitive positioning in enteral access.

What specific safety features does the allowed ENvue patent include related to MRI use?

The allowed application includes MRI-related safety design elements that limit RF-induced heating below defined thresholds. According to ENvue Medical, those elements are intended to address controlled heating concerns during MRI exposure for the feeding tube design.

What are the key technical elements claimed in FEED’s allowed patent application No. 18/199,059?

Key claims cover a distal-tip camera, an embedded electromagnetic sensor architecture, and combined navigation-plus-visualization capabilities. According to ENvue Medical, these elements together enable real-time internal imaging and continuous positional tracking during placement.